One such inhibitory receptor that is expressed on CTLs and Treg cells during exhaustion is lymphocyte activation gene 3 protein (LAG3), with efficacy studies demonstrating an enhanced response in melanoma patients treated with both nivolumab and relatlimab, an anti-LAG3 mAb [7]. Here, LAG3 is linked to melanoma.